ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have earned an average rating of “Moderate Buy” from the four brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $149.00.

A number of research firms have recently weighed in on ICUI. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Raymond James increased their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. KeyCorp boosted their target price on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th.

ICU Medical Stock Down 0.0 %

ICUI stock opened at $174.47 on Friday. The stock has a market cap of $4.25 billion, a P/E ratio of -71.21 and a beta of 0.65. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The stock’s fifty day simple moving average is $154.77 and its two-hundred day simple moving average is $124.01. ICU Medical has a 1-year low of $78.28 and a 1-year high of $181.87.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. During the same period in the previous year, the firm earned $1.58 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Analysts expect that ICU Medical will post 3.76 EPS for the current year.

Insider Transactions at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,096,771.78. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The disclosure for this sale can be found here. Insiders sold 28,552 shares of company stock valued at $4,537,802 over the last three months. Company insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently added to or reduced their stakes in the business. Motco bought a new position in ICU Medical in the 1st quarter worth about $29,000. Innealta Capital LLC purchased a new stake in ICU Medical in the second quarter valued at approximately $32,000. GAMMA Investing LLC raised its stake in ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 133 shares in the last quarter. EntryPoint Capital LLC lifted its position in ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.